In Switzerland, the median time from first submission by a pharmaceutical company to availability of a medicinal product to patients is almost 650 days.
Interpharma members currently invest around CHF 6.5 billion a year in research and development in Switzerland.
show more articles
The chances of a cure for cancer in children have risen from 40% to 80% between 1973 and 2012.
Between 1990 and 2015 the mortality rate for breast cancer fell by 30%.
Pharmacological and technological innovations will bring about a fundamental change in the way medicines are developed and used, enabling new approaches to be adopted in research.
The pharmaceutical industry in Switzerland will also need attractive framework conditions in future, including legal certainty, open export markets and the availability of labour.
Interpharma, the association of Switzerland’s research-based pharmaceutical industry, was founded in Basel in 1933.
Interpharma informs the public about issues that are important to the research-based pharmaceutical industry in Switzerland, including the pharma market in Switzerland, healthcare and biomedical research.
Information on our key figures and activities in the financial year 2019
More about the tasks and overriding aims of Interpharma
Latest information and media contacts for media representatives